{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:00:59Z","timestamp":1784977259067,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayer Hispania, S.L."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We aimed to describe treatment patterns of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who progressed after receiving darolutamide in a real-world setting, and according to the standard clinical practice in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multicenter, observational, retrospective study conducted at the urology and oncology departments of 17 Spanish hospitals that participated in the ARAMIS trial and its rollover study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      85 patients, with a median age of 76\u00a0years, were included in the study. 49 patients (57.6%) progressed to mCRPC, with metastases located mainly in bone. Only 35 of them (71.4%) received at least one subsequent therapy. The most common first-line treatments after darolutamide were abiraterone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922, 63%) and docetaxel (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910, 29%), with a median (IQR) treatment duration of 7.6\u00a0months (4.7, 12.7) and 4.8\u00a0months (3.8, 5.8), respectively; besides, the most frequent first-line\/second-line treatment sequences were abiraterone\u2013docetaxel and docetaxel\u2013cabazitaxel. In addition, only 20% of patients with bone metastases received osteoclast-targeted therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These real-world practice patterns suggest a lack of consensus in Spanish clinical practice for the management of patients with mCRPC, indicating that there is a need for more standardized strategies and unification of the criteria to make decisions in accordance with the recommendations of international clinical practice guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04233-8","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:28:26Z","timestamp":1770748106000},"page":"3287-3295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-1331","authenticated-orcid":false,"given":"Javier","family":"Puente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Campanario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marmolejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Andr\u00e9s","family":"Cantero-Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"G\u00f3mez-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Rodr\u00edguez Antol\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Ribal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Picola Brau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Ledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gonz\u00e1lez-Enguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Bison\u00f3 Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Benejam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Gil Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Garcia-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Folqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Casas-Nebra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"4233_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41391-024-00803-5","volume":"28","author":"ND Shore","year":"2024","unstructured":"Shore ND, Antonarakis ES, Ross AE, Marshall CH, Stratton KL, Ayanambakkam A, et al. A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024;28:250\u20139. https:\/\/doi.org\/10.1038\/s41391-024-00803-5.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4233_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, den Van Bergh RCN, Briers E, den Van Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","journal-title":"Eur Urol"},{"key":"4233_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","volume":"34","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Gillessen S. Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents. Ann Oncol. 2023;34:557\u201363. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.015.","journal-title":"Ann Oncol"},{"key":"4233_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.acuro.2021.11.004","volume":"46","author":"AA Asensio","year":"2022","unstructured":"Asensio AA, Ossorio JA, Olmo JC, Abal VC, Soto AJ, Espinos EL, et al. C\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n no metast\u00e1sico: recomendaciones de manejo. Actas Urol Esp. 2022;46:193\u2013213. https:\/\/doi.org\/10.1016\/j.acuro.2021.11.004.","journal-title":"Actas Urol Esp"},{"key":"4233_CR5","doi-asserted-by":"publisher","first-page":"175.e9","DOI":"10.1016\/j.urolonc.2024.03.005","volume":"42","author":"BA Yanada","year":"2024","unstructured":"Yanada BA, Homewood D, Dias BH, Ogluszko C, Corcoran NM. The treatment landscape of nonmetastatic castrate resistant prostate cancer: a contemporary perspective. Urol Oncol. 2024;42:175.e9-18. https:\/\/doi.org\/10.1016\/j.urolonc.2024.03.005.","journal-title":"Urol Oncol"},{"key":"4233_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23:469\u201393. https:\/\/doi.org\/10.6004\/jnccn.2025.0052.","journal-title":"J Natl Compr Canc Netw"},{"key":"4233_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/rru.s360444","volume":"14","author":"F Turco","year":"2022","unstructured":"Turco F, Gillessen S, Cathomas R, Buttigliero C, Vogl UM. Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs. Res Rep Urol. 2022;14:339\u201350. https:\/\/doi.org\/10.2147\/rru.s360444.","journal-title":"Res Rep Urol"},{"key":"4233_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/rru.s385257","volume":"15","author":"S Ferretti","year":"2023","unstructured":"Ferretti S, Mercinelli C, Marandino L, Litterio G, Marchioni M, Schips L. Metastatic castration-resistant prostate cancer: insights on current therapy and promising experimental drugs. Res Rep Urol. 2023;15:243\u201359. https:\/\/doi.org\/10.2147\/rru.s385257.","journal-title":"Res Rep Urol"},{"key":"4233_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","volume":"87","author":"E Francini","year":"2025","unstructured":"Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, et al. Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review. Eur Urol. 2025;87:29\u201346. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.008.","journal-title":"Eur Urol"},{"key":"4233_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30:257\u201364. https:\/\/doi.org\/10.1038\/s41591-023-02704-x.","journal-title":"Nat Med"},{"key":"4233_CR11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Curr Treat Options Oncol. 2024;25:914\u201331. https:\/\/doi.org\/10.1007\/s11864-024-01215-2.","journal-title":"Curr Treat Options Oncol"},{"key":"4233_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41391-024-00906-z","volume":"28","author":"HD McManus","year":"2024","unstructured":"McManus HD, Dorff T, Morgans AK, Sartor O, Shore N, Armstrong AJ. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. 2024;28:672\u201383. https:\/\/doi.org\/10.1038\/s41391-024-00906-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4233_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2217\/fon-2022-1131","volume":"19","author":"J Carles","year":"2023","unstructured":"Carles J, Medina-Lopez RA, Puente J, G\u00f3mez-Ferrer \u00c1, Nebra JC, Medina MIS, et al. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. Future Oncol. 2023;19:819\u201328. https:\/\/doi.org\/10.2217\/fon-2022-1131.","journal-title":"Future Oncol"},{"key":"4233_CR14","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2001342.","journal-title":"N Engl J Med"},{"key":"4233_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113342","volume":"195","author":"ND Shore","year":"2023","unstructured":"Shore ND, Fizazi K, Tammela TLJ, Luz M, Salas MP, Ouellette P, et al. Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study. Eur J Cancer. 2023;195:113342. https:\/\/doi.org\/10.1016\/j.ejca.2023.113342.","journal-title":"Eur J Cancer"},{"key":"4233_CR16","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). 1996. https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/."},{"key":"4233_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26:1033\u20139. https:\/\/doi.org\/10.1002\/pds.4297.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4233_CR18","unstructured":"Agencia Estatal Bolet\u00edn Oficial del Estado. Real Decreto 957\/2020 ddn, por el que se regulan los estudios observacionales con medicamentos de uso humano. 2020. https:\/\/www.boe.es\/buscar\/doc.php?id=BOE-A-2020-14960."},{"key":"4233_CR19","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1815671.","journal-title":"N Engl J Med"},{"key":"4233_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.157","volume":"41","author":"S Oudard","year":"2023","unstructured":"Oudard S, Hadaschik BA, Antoni L, Diels J, Luccarini I, Thilakarathne P, et al. Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a post-hoc analysis of the SPARTAN phase III trial. J Clin Oncol. 2023;41:157. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.157.","journal-title":"J Clin Oncol"},{"key":"4233_CR21","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2003892.","journal-title":"N Engl J Med"},{"key":"4233_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2025.43.5_suppl.74","volume":"43","author":"E Efstathiou","year":"2025","unstructured":"Efstathiou E, Li W, Roose J, Kerr BT, Orji C, Yeh N, et al. Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018-2023. J Clin Oncol. 2025;43:74. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.74.","journal-title":"J Clin Oncol"},{"key":"4233_CR23","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1007\/s12325-022-02073-w","volume":"39","author":"A Leith","year":"2022","unstructured":"Leith A, Kim J, Ribbands A, Clayton E, Yang L, Ghate SR. Real-world treatment patterns in metastatic castration-resistant prostate cancer across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan. Adv Ther. 2022;39:2236\u201355. https:\/\/doi.org\/10.1007\/s12325-022-02073-w.","journal-title":"Adv Ther"},{"key":"4233_CR24","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14796694.2025.2470616","volume":"21","author":"E Castro","year":"2025","unstructured":"Castro E, Orji C, Ribbands A, Butcher J, Walley M, Li W, et al. Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe. Future Oncol. 2025;21:1085\u201399. https:\/\/doi.org\/10.1080\/14796694.2025.2470616.","journal-title":"Future Oncol"},{"key":"4233_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.clgc.2023.12.011","volume":"22","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Bianchi A, Malandra S, Porcaro AB, Fantinel E, Negrelli R, et al. Parp inhibitors in metastatic prostate cancer: a comprehensive systematic review and meta-analysis of existing evidence. Clin Genitourin Cancer. 2024;22:402-12.e17. https:\/\/doi.org\/10.1016\/j.clgc.2023.12.011.","journal-title":"Clin Genitourin Cancer"},{"key":"4233_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/coc.0000000000000528","volume":"42","author":"RB Den","year":"2019","unstructured":"Den RB, George D, Pieczonka C, McNamara M. Ra-223 treatment for bone metastases in castrate-resistant prostate cancer: practical management issues for patient selection. Am J Clin Oncol. 2019;42:399\u2013406. https:\/\/doi.org\/10.1097\/coc.0000000000000528.","journal-title":"Am J Clin Oncol"},{"key":"4233_CR27","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13749","volume":"25","author":"EA Goode","year":"2023","unstructured":"Goode EA, Wang N, Munkley J. Prostate cancer bone metastases biology and clinical management (review). Oncol Lett. 2023;25:163. https:\/\/doi.org\/10.3892\/ol.2023.13749.","journal-title":"Oncol Lett"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04233-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04233-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04233-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:29:14Z","timestamp":1784975354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04233-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4233"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04233-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Javier Puente reports consulting fees from Pfizer and Roche; payment or honoraria from AstraZeneca, Gilead, Eisai, Janssen, MSD, Pfizer, BMS, and Merck; participation on a Data Safety Monitoring Board or Advisory Board at AstraZeneca, Bayer, Janssen, MSD, Pfizer, BMS, and Merck; and support or travel from Merck, MSD, AstraZeneca, and Janssen. Alfredo Rodr\u00edguez Antol\u00edn reports the following: consultant or advisory role: Astellas, Ipsen Pharma; PI in clinical trials: Janssen, Bayer, Astellas, AstraZeneca; speaking: AstraZeneca, Bayer, Janssen, MSD, Astellas; other: travel support from Ipsen, Janssen. Maria J. Ribal reports the following: clinical trials participation: Bayer, Janssen, Unicancer, Astellas, Seagen, Urogenpharma, Fidia, DMIA; speaker honoraria 2 last years: Bayer, Johnson and Johnson. Jose Garcia-Sanchez reports speaker honorarium from Roche, Pfizer, Lilly, Astellas, BMS; advisory honorarium from Regeneron, Pfizer; travel grants from Roche, MSD, BMS, AstraZeneca. Joan Folqu\u00e9 is an employee of Bayer Hispania S.L. Javier Casas-Nebra reports speaker honorarium from Janssen, Astellas, Bayer. Rub\u00e9n Campanario, David Marmolejo, Juan Andr\u00e9s Cantero-Mellado, \u00c1lvaro G\u00f3mez-Ferrer, NataliaPicola Brau, Mar\u00eda Jos\u00e9 Ledo, Carlos Hernandez, Carlos Llorente, Carmen Gonz\u00e1lez-Enguita, \u00c1lvaro Bison\u00f3, Joan Benejam, and Jes\u00fas Gil Guijarro report no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Regional Independent Reference Ethics Committee of Galicia, Spain (CEIC 2023\/371).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the enrolled patients whenever feasible (i.e., when the patient died or was lost to follow-up, it was not mandatory to obtain informed consent), according to the applicable Spanish regulations (Royal Decree 957\/2020).","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}